

**A novel bis(pinacolato)diboron-mediated N–O bond deoxygenative route to C6
benzotriazolyl purine nucleoside derivatives†**

Vikram Basava,^a Lijia Yang,^a Padmanava Pradhan,^a and Mahesh K. Lakshman^{*a,b}

^a*Department of Chemistry, The City College of New York, 160 Convent Avenue, New York, New York, 10031, USA. Email: mlakshman@ccny.cuny.edu*

^b*The Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, New York 10016, USA*

TABLE OF CONTENTS

Information	Page
O^6 -(7-Azabenzotriazol-1-yl)-2',3',5'-tri- O -(<i>t</i> -butyldimethylsilyl)inosine (9)	S-5
O^6 -(7-Azabenzotriazol-1-yl)-3',5'-di- O -(<i>t</i> -butyldimethylsilyl)-2'-deoxyinosine (10)	S-5
O^6 -(6-Chlorobenzotriazol-1-yl)-2',3',5'-tri- O -(<i>t</i> -butyldimethylsilyl)inosine (11)	S-6
O^6 -(6-Chlorobenzotriazol-1-yl)-3',5'-di- O -(<i>t</i> -butyldimethylsilyl)-2'-deoxyinosine (12)	S-7
O^6 -(6-Chlorobenzotriazol-1-yl)-2',3',5'-tri- O -(<i>t</i> -butyldimethylsilyl)guanosine (13)	S-8
O^6 -(6-Chlorobenzotriazol-1-yl)-3',5'-di- O -(<i>t</i> -butyldimethylsilyl)-2'-deoxyguanosine (14)	S-8
2-Bromo-6-(2,3-dibromopropoxy)-2',3',5'-tri- O -(<i>t</i> -butyldimethylsilyl)inosine (17)	S-9
1-[^{5,6} -Dichloro-1 <i>H</i> -benzotriazo-1-yl]oxy]- <i>N,N,N'N'</i> -tetramethylphosphanediamine (36)	S-10
Reduction of 6-(6-chlorobenzotriazol-1-yl)-9-[2,3,5-tri- O -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (27b)	S-10
Reduction of 6-(5-chlorobenzotriazol-1-yl)-9-[3,5-di- O -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (28a)	S-11
Reduction of 6-(6-chlorobenzotriazol-1-yl)-9-[3,5-di- O -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (28b)	S-11
500 MHz ¹ H NMR spectrum of 6-(benzotriazol-1-yl)-9-[2,3,5-tri- O -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (2) in CDCl ₃	S-12
125 MHz ¹³ C NMR spectrum of 6-(benzotriazol-1-yl)-9-[2,3,5-tri- O -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (2) in CDCl ₃	S-13
500 MHz ¹ H NMR spectrum of 6-(benzotriazol-1-yl)-9-[3,5-di- O -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (5) in CDCl ₃	S-14
125 MHz ¹³ C NMR spectrum of 6-(benzotriazol-1-yl)-9-[3,5-di- O -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (5) in CDCl ₃	S-15

butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (5) in CDCl ₃	
500 MHz ¹ H NMR spectrum of O ⁶ -(7-azabenzotriazol-1-yl)-2',3',5'-tri-O-(<i>t</i> -butyldimethylsilyl)inosine (9) in CDCl ₃	S-16
125 MHz ¹³ C NMR spectrum of O ⁶ -(7-azabenzotriazol-1-yl)-2',3',5'-tri-O-(<i>t</i> -butyldimethylsilyl)inosine (9) in CDCl ₃	S-17
500 MHz ¹ H NMR spectrum of O ⁶ -(7-azabenzotriazol-1-yl)-3',5'-di-O-(<i>t</i> -butyldimethylsilyl)-2'-deoxyinosine (10) in CDCl ₃	S-18
125 MHz ¹³ C NMR spectrum of O ⁶ -(7-azabenzotriazol-1-yl)-3',5'-di-O-(<i>t</i> -butyldimethylsilyl)-2'-deoxyinosine (10) in CDCl ₃	S-19
500 MHz ¹ H NMR spectrum of O ⁶ -(6-chlorobenzotriazol-1-yl)-2',3',5'-tri-O-(<i>t</i> -butyldimethylsilyl)inosine (11) in CDCl ₃	S-20
125 MHz ¹³ C NMR spectrum of O ⁶ -(6-chlorobenzotriazol-1-yl)-2',3',5'-tri-O-(<i>t</i> -butyldimethylsilyl)inosine (11) in CDCl ₃	S-21
500 MHz ¹ H NMR spectrum of O ⁶ -(6-chlorobenzotriazol-1-yl)-3',5'-di-O-(<i>t</i> -butyldimethylsilyl)-2'-deoxyinosine (12) in CDCl ₃	S-22
125 MHz ¹³ C NMR spectrum of O ⁶ -(6-chlorobenzotriazol-1-yl)-3',5'-di-O-(<i>t</i> -butyldimethylsilyl)-2'-deoxyinosine (12) in CDCl ₃	S-23
500 MHz ¹ H NMR spectrum of O ⁶ -(6-chlorobenzotriazol-1-yl)-2',3',5'-tri-O-(<i>t</i> -butyldimethylsilyl)guanosine (13) in CDCl ₃	S-24
125 MHz ¹³ C NMR spectrum of O ⁶ -(6-chlorobenzotriazol-1-yl)-2',3',5'-tri-O-(<i>t</i> -butyldimethylsilyl)guanosine (13) in CDCl ₃	S-25
500 MHz ¹ H NMR spectrum of O ⁶ -(6-chlorobenzotriazol-1-yl)-3',5'-di-O-(<i>t</i> -butyldimethylsilyl)-2'-deoxyguanosine (14) in CDCl ₃	S-26
125 MHz ¹³ C NMR spectrum of O ⁶ -(6-chlorobenzotriazol-1-yl)-3',5'-di-O-(<i>t</i> -butyldimethylsilyl)-2'-deoxyguanosine (14) in CDCl ₃	S-27
500 MHz ¹ H NMR spectrum of O ⁶ -allyl-2',3',5'-tri-O-(<i>t</i> -butyldimethylsilyl)-2-bromoinosine (16) in CDCl ₃	S-28
125 MHz ¹³ C NMR spectrum of O ⁶ -allyl-2',3',5'-tri-O-(<i>t</i> -butyldimethylsilyl)-2-bromoinosine (16) in CDCl ₃	S-29
500 MHz ¹ H NMR spectrum of 2-bromo-6-(2,3-dibromopropoxy)-2',3',5'-tri-O-(<i>t</i> -butyldimethylsilyl)inosine (17) in CDCl ₃	S-30
500 MHz ¹ H NMR spectrum of 2',3',5'-tri-O-(<i>t</i> -butyldimethylsilyl)-2-phenylinosine (18) in CDCl ₃	S-31
125 MHz ¹³ C NMR spectrum of 2',3',5'-tri-O-(<i>t</i> -butyldimethylsilyl)-2-phenylinosine (18) in CDCl ₃	S-32
500 MHz ¹ H NMR spectrum of O ⁶ -(benzotriazol-1-yl)-2',3',5'-tri-O-(<i>t</i> -butyldimethylsilyl)-2-phenylinosine (19) in C ₆ D ₆	S-33
125 MHz ¹³ C NMR spectrum of O ⁶ -(benzotriazol-1-yl)-2',3',5'-tri-O-(<i>t</i> -butyldimethylsilyl)-2-phenylinosine (19) in C ₆ D ₆	S-34
500 MHz ¹ H NMR spectrum of 2-amino-6-(benzotriazol-1-yl)-9-[2,3,5-tri-O-(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (20) in CDCl ₃	S-35
125 MHz ¹³ C NMR spectrum of 2-amino-6-(benzotriazol-1-yl)-9-[2,3,5-tri-O-(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (20) in CDCl ₃	S-36
500 MHz ¹ H NMR spectrum of 2-amino-6-(benzotriazol-1-yl)-9-[3,5-di-O-(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (22) in CDCl ₃	S-37

125 MHz ^{13}C NMR spectrum of 2-amino-6-(benzotriazol-1-yl)-9-[3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (22) in CDCl_3	S-38
500 MHz ^1H NMR spectrum of 6-(azabenzotriazol-1-yl)-9-[3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (24) in CDCl_3	S-39
500 MHz ^1H NMR spectrum of <i>N</i> ¹ -[6-[9-(2,3,5-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl)]purinyl]-2',3',5'-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)inosine (25) in CDCl_3	S-40
125 MHz ^{13}C NMR spectrum of <i>N</i> ¹ -[6-[9-(2,3,5-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl)]purinyl]-2',3',5'-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)inosine (25) in CDCl_3	S-41
500 MHz ^1H NMR spectrum of <i>N</i> ¹ -[6-[9-(3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl)]purinyl]-3',5'-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2'-deoxyinosine (26) in CDCl_3	S-42
500 MHz ^1H NMR spectrum of 6-(5-chlorobenzotriazol-1-yl)-9-[2,3,5-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (27a) in CDCl_3	S-43
125 MHz ^{13}C NMR spectrum of 6-(5-chlorobenzotriazol-1-yl)-9-[2,3,5-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (27a) in CDCl_3	S-44
500 MHz ^1H NMR spectrum of 6-(6-chlorobenzotriazol-1-yl)-9-[2,3,5-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (27b) in CDCl_3	S-45
125 MHz ^{13}C NMR spectrum of 6-(6-chlorobenzotriazol-1-yl)-9-[2,3,5-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (27b) in CDCl_3	S-46
500 MHz ^1H NMR spectrum of 6-(5-chlorobenzotriazol-1-yl)-9-[3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (28a) in CDCl_3	S-47
125 MHz ^{13}C NMR spectrum of 6-(5-chlorobenzotriazol-1-yl)-9-[3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (28a) in CDCl_3	S-48
NOESY spectrum of 6-(5-chlorobenzotriazol-1-yl)-9-[3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (28a) in CDCl_3	S-49
500 MHz ^1H NMR spectrum of 6-(6-chlorobenzotriazol-1-yl)-9-[3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (28b) in CDCl_3	S-50
125 MHz ^{13}C NMR spectrum of 6-(6-chlorobenzotriazol-1-yl)-9-[3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (28b) in CDCl_3	S-51
500 MHz ^1H NMR spectrum of 2-amino-6-(5-chlorobenzotriazol-1-yl)-9-[2,3,5-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (29a) in CDCl_3	S-52
125 MHz ^{13}C NMR spectrum of 2-amino-6-(5-chlorobenzotriazol-1-yl)-9-[2,3,5-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (29a) in CDCl_3	S-53
NOESY spectrum of 2-amino-6-(5-chlorobenzotriazol-1-yl)-9-[2,3,5-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (29a) in CDCl_3	S-54
500 MHz ^1H NMR spectrum of 2-amino-6-(6-chlorobenzotriazol-1-yl)-9-[2,3,5-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (29b) in CDCl_3	S-55
125 MHz ^{13}C NMR spectrum of 2-amino-6-(6-chlorobenzotriazol-1-yl)-9-[2,3,5-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (29b) in CDCl_3	S-56
500 MHz ^1H NMR spectrum of a mixture of 2-amino-6-(5-chlorobenzotriazol-1-yl)-9-[3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (30a) and 2-amino-6-(6-chlorobenzotriazol-1-yl)-9-[3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (30b) in CDCl_3	S-57
125 MHz ^{13}C NMR spectrum of a mixture of 2-amino-6-(5-chlorobenzotriazol-1-yl)-9-[3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (30a) and 2-amino-6-(6-chlorobenzotriazol-1-yl)-9-[3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (30b) in CDCl_3	S-58

yl]-9-[3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (30a) and 2-amino-6-(6-chlorobenzotriazol-1-yl)-9-[3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (30b) in CDCl ₃	
500 MHz ¹ H NMR spectrum of 6-(benzotriazol-1-yl)-2-phenyl-9-[2,3,5-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (31) in C ₆ D ₆	S-59
125 MHz ¹³ C NMR spectrum of 6-(benzotriazol-1-yl)-2-phenyl-9-[2,3,5-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (31) in C ₆ D ₆	S-60
500 MHz ¹ H NMR spectrum of 1,2,4-trichloro-5-nitrobenzene (33) in DMSO- <i>d</i> ₆	S-61
125 MHz ¹³ C NMR spectrum of 1,2,4-trichloro-5-nitrobenzene (33) in DMSO- <i>d</i> ₆	S-62
500 MHz ¹ H NMR spectrum of 5,6-dichloro-1-hydroxy-1 <i>H</i> -benzotriazole (34) in DMSO- <i>d</i> ₆	S-63
125 MHz ¹³ C NMR spectrum of 5,6-dichloro-1-hydroxy-1 <i>H</i> -benzotriazole (34) in DMSO- <i>d</i> ₆	S-64
500 MHz ¹ H NMR spectrum of 5,6-dichloro-1 <i>H</i> -benzotriazole (35) in DMSO- <i>d</i> ₆	S-65
500 MHz ¹ H NMR spectrum of 1-[(5,6-dichloro-1 <i>H</i> -benzotriazol-1-yl)oxy]- <i>N,N,N'N'</i> -tetramethylphosphane diamine (36) in CDCl ₃	S-66
125 MHz ¹³ C NMR spectrum of 1-[(5,6-dichloro-1 <i>H</i> -benzotriazol-1-yl)oxy]- <i>N,N,N'N'</i> -tetramethylphosphane diamine (36) in CDCl ₃	S-67
202 MHz ³¹ P NMR spectrum of 1-[(5,6-dichloro-1 <i>H</i> -benzotriazol-1-yl)oxy]- <i>N,N,N'N'</i> -tetramethylphosphane diamine (36) in CDCl ₃	S-68
500 MHz ¹ H NMR spectrum of <i>O</i> ⁶ -(5,6-dichlorobenzotriazol-1-yl)-3',5'-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2'-deoxyinosine (40) in CDCl ₃	S-69
125 MHz ¹³ C NMR spectrum of <i>O</i> ⁶ -(5,6-dichlorobenzotriazol-1-yl)-3',5'-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2'-deoxyinosine (40) in CDCl ₃	S-70
500 MHz ¹ H NMR spectrum of <i>O</i> ⁶ -(5,6-dichlorobenzotriazol-1-yl)-2',3',5'-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)inosine (41) in CDCl ₃	S-71
125 MHz ¹³ C NMR spectrum of <i>O</i> ⁶ -(5,6-dichlorobenzotriazol-1-yl)-2',3',5'-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)inosine (41) in CDCl ₃	S-72
500 MHz ¹ H NMR spectrum of 6-(5,6-dichlorobenzotriazol-1-yl)-9-[3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (42) in CDCl ₃	S-73
125 MHz ¹³ C NMR spectrum of 6-(5,6-dichlorobenzotriazol-1-yl)-9-[3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (42) in CDCl ₃	S-74
500 MHz ¹ H NMR spectrum of 6-(5,6-dichlorobenzotriazol-1-yl)-9-[2,3,5-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (43) in CDCl ₃	S-75
125 MHz ¹³ C NMR spectrum of 6-(5,6-dichlorobenzotriazol-1-yl)-9-[2,3,5-tri- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- β -D-ribofuranosyl]purine (43) in CDCl ₃	S-76

***O*⁶-(7-Azabenzotriazol-1-yl)-2',3',5'-tri-*O*-(*t*-butyldimethylsilyl)inosine (9).**

In a clean, dry, screw-cap reaction vial a mixture of 2',3',5'-tri-*O*-(*t*-butyldimethylsilyl)inosine (200 mg, 0.327 mmol), (7-azabenzotriazol-1-yloxy) tripyrrolidinophosphonium hexafluorophosphate (PyAOP) (170.65 mg, 0.327 mg), and DBU (49 μ L, 49.8 mmol) in anhydrous CH₃CN (2.8 mL) was stirred under a nitrogen atmosphere at room temperature, for 18 h. A second aliquot of PyAOP (170.65 mg, 0.327 mg) and DBU (49 μ L, 49.8 mmol) were added and the stirring was continued at room temperature for 7 h. The mixture was diluted with EtOAc and washed with water containing a small amount of NaCl. The aqueous layer was back extracted with EtOAc and the combined organic layer was dried with anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure. The crude material was purified by flash chromatography (SiO₂, elution with 20% and 30% EtOAc in hexanes) to give 124.3 mg (52% yield) of compound **9** as a white, fluffy solid. *R*_f (3:1 EtOAc in acetone) = 0.93. ¹H NMR (500 MHz, CDCl₃): δ 8.70 (d, *J* = 4.4 Hz, 1H, Ar-H), 8.59 (s, 1H, Ar-H), 8.48 (d, *J* = 8.3 Hz, 1H, Ar-H), 8.37 (s, 1H, Ar-H), 7.45 (dd, *J* = 4.4, 8.3 Hz, 1H, Ar-H), 6.13 (d, *J* = 3.9 Hz, 1H, H-1'), 4.57 (t, *J* = 3.9 Hz, 1H, H-2'), 4.35 (t, *J* = 4.4 Hz, 1H, H-3'), 4.18–4.16 (m, 1H, H-4'), 4.05 (dd, *J* = 3.1, 11.4 Hz, 1H, H-5'), 3.81 (dd, *J* = 1.5, 11.2 Hz, 1H, H-5'), 0.97, 0.93, and 0.83 (3s, 27H, *t*-Bu), 0.16, 0.15, 0.11, 0.10, 0.00, and -0.12 (6s, 18H, SiCH₃). ¹³C NMR (125 MHz, CDCl₃): δ 159.1, 154.1, 151.9, 151.4, 144.0, 141.1, 135.3, 129.7, 121.0, 120.1, 89.2, 85.3, 76.6, 71.4, 62.2, 31.1, 26.3, 26.0, 25.9, 18.8, 18.3, 18.1, -4.1, -4.5, -4.56, -4.6, -5.1, -5.2. HRMS (ESI/TOF) calcd for C₃₃H₅₇N₈O₅Si₃ [M + H]⁺ 729.3760, found 729.3773.

***O*⁶-(7-Azabenzotriazol-1-yl)-3',5'-di-*O*-(*t*-butyldimethylsilyl)-2'-deoxyinosine (10).**

As described for the synthesis of compound **9**, this reaction was carried out by the reaction of 3',5'-di-*O*-(*t*-butyldimethylsilyl)-2'-deoxyinosine (157.3 mg, 0.327 mmol) with PyAOP (341.3 mg, 0.655 mmol) and DBU (97.9 μ L, 0.655 mmol) in anhydrous CH₃CN (2.8 mL), at room temperature over 25 h. Workup as described for compound **9** and purification by flash chromatography (SiO₂, elution with 30% EtOAc in hexanes) gave 130.4 mg (66% yield) of compound **10** as a white, fluffy solid. R_f (3:1 EtOAc in acetone) = 0.90. ¹H NMR (500 MHz, CDCl₃): δ 8.69 (d, *J* = 4.4 Hz, 1H, Ar-H), 8.51 (s, 1H, Ar-H), 8.48 (d, *J* = 8.3 Hz, 1H, Ar-H), 8.37 (s, 1H, Ar-H), 7.46 (dd, *J* = 4.4, 8.2 Hz, 1H, Ar-H), 6.53 (t, *J* = 6.4 Hz, 1H, H-1'), 4.63–4.60 (m, 1H, H-3'), 4.05–4.03 (m, 1H, H-4'), 3.90 (dd, *J* = 3.6, 11.5 Hz, 1H, H-5'), 3.79 (dd, *J* = 3.0, 11.2 Hz, 1H, H-5'), 2.61 (app quint, J_{app} ~ 6.2 Hz, 1H, H-2'), 2.49 (ddd, *J* = 4.5, 5.9, 12.4 Hz, 1H, H-2'), 0.91 and 0.90 (2s, 18H, *t*-Bu), 0.10 (1s, 12H, SiCH₃). ¹³C NMR (125 MHz, CDCl₃): δ 158.9, 153.6, 151.8, 151.2, 143.5, 140.9, 135.1, 129.6, 120.8, 119.9, 88.1, 85.1, 71.5, 62.6, 41.7, 26.0, 25.7, 18.4, 18.0, -4.6, -4.8, -5.4, -5.5. HRMS (ESI/TOF) calcd for C₂₇H₄₃N₈O₄Si₂ [M + H]⁺ 599.2946, found 599.2947.

O⁶-(6-Chlorobenzotriazol-1-yl)-2',3',5'-tri-*O*-(*t*-butyldimethylsilyl)inosine (11**).**

As described for the synthesis of compound **9**, this reaction was carried out by the reaction of 2',3',5'-tri-*O*-(*t*-butyldimethylsilyl)inosine (508.3 mg, 0.832 mmol) with (6-chlorobenzotriazol-1*H*-yloxy)trispyrrolidinophosphonium hexafluorophosphate (PyClocK) (923.3 mg, 1.664 mmol) and DBU (248 μ L, 1.664 mmol) in anhydrous CH₃CN (7 mL), at room temperature over 23 h. Workup as described for compound **9** and purification by flash chromatography (SiO₂, elution with 10% EtOAc in hexanes) gave 349 mg (55% yield) of compound **11** as a white, fluffy solid. R_f (3:1 EtOAc in acetone) = 0.95. ¹H NMR (500 MHz, CDCl₃): δ 8.63 (s, 1H, Ar-H), 8.41 (s, 1H, Ar-H), 8.06 (d, *J* = 8.7 Hz, 1H, Ar-H), 7.49 (s,

1H, Ar-H), 7.42 (d, J = 9.3 Hz, 1H, Ar-H), 6.16 (d, J = 4.4 Hz, 1H, H-1'), 4.58 (t, J = 4.4 Hz, 1H, H-2'), 4.34 (t, J = 4.1 Hz, 1H, H-3'), 4.19–4.17 (m, 1H, H-4'), 4.05 (dd, J = 3.2, 11.5 Hz, 1H, H-5'), 3.82 (dd, J = 2.0, 11.7 Hz, 1H, H-5'), 0.97, 0.93, and 0.82 (3s, 27H, *t*-Bu), 0.17, 0.16, 0.11, 0.10, 0.00, and -0.16 (6s, 18H, SiCH₃). ¹³C NMR (125 MHz, CDCl₃): δ 158.7, 153.9, 151.3, 144.0, 142.0, 135.3, 129.5, 126.1, 121.5, 109.9, 108.5, 88.8, 85.3, 76.4, 71.4, 62.1, 26.0, 25.8, 25.6, 18.5, 18.0, 17.8, -4.4, -4.7, -4.8, -5.0, -5.4, -5.5. HRMS (ESI/TOF) calcd for C₃₄H₅₆ClN₇O₅Si₃Na [M + Na]⁺ 784.3231, found 784.3220.

O⁶-(6-Chlorobenzotriazol-1-yl)-3',5'-di-O-(*t*-butyldimethylsilyl)-2'-deoxyinosine (12).

As described for the synthesis of compound **9**, this reaction was carried out by the reaction of 3',5'-di-O-(*t*-butyldimethylsilyl)-2'-deoxyinosine (400 mg, 0.832 mmol) with PyClocK (923.3 mg, 1.66 mmol) and DBU (248 μ L, 1.66 mmol) in CH₃CN (7 mL), at room temperature over 23 h. Workup as described for compound **9** and purification by flash chromatography (SiO₂, elution with 20% EtOAc in hexanes) gave 392.4 mg (74% yield) of compound **12** as a white, fluffy solid. R_f (3:1 EtOAc in acetone) = 0.95. ¹H NMR (500 MHz, CDCl₃): δ 8.54 (s, 1H, Ar-H), 8.41 (s, 1H, Ar-H), 8.05 (d, J = 8.8 Hz, 1H, Ar-H), 7.48 (d, J = 1.0 Hz, 1H, Ar-H), 7.41 (dd, J = 1.4, 9.2 Hz, 1H, Ar-H), 6.54 (t, J = 6.1 Hz, 1H, H-1'), 4.65–4.63 (m, 1H, H-3'), 4.04–4.06 (m, 1H, H-4'), 3.91 (dd, J = 3.7, 11.5 Hz, 1H, H-5'), 3.80 (dd, J = 2.7, 11.4 Hz, 1H, H-5'), 2.64 (app quint, J_{app} ~ 6.2 Hz, 1H, H-2'), 2.51 (ddd, J = 4.6, 5.9, 13.1 Hz, 1H, H-2'), 0.92 and 0.91 (2s, 18H, *t*-Bu), 0.10 (1s, 12H, SiCH₃). ¹³C NMR (125 MHz, CDCl₃): δ 158.8, 153.7, 151.3, 143.7, 142.0, 135.4, 129.5, 126.2, 121.6, 119.9, 108.6, 88.2, 85.1, 71.6, 62.6, 41.7, 26.0, 25.7, 18.4, 18.0, -4.6, -4.8, -5.4, -5.5. HRMS (ESI/TOF) calcd for C₂₈H₄₂ClN₇O₄Si₂Na [M + Na]⁺ 654.2423, found 654.2418.

O⁶-(6-Chlorobenzotriazol-1-yl)-2',3',5'-tri-O-(*t*-butyldimethylsilyl)guanosine (13).

As described in the synthesis of compound **9**, this reaction was carried out by the reaction of 2',3',5'-tri-*O*-(*t*-butyldimethylsilyl)guanosine (300 mg, 0.479 mmol) with PyClocK (531.8 mg, 0.958 mmol) and DBU (143 μ L, 0.958 mmol) in CH₃CN (4 mL), at room temperature over 20 h. Workup as described for compound **9** and purification by flash chromatography (SiO₂, elution with 10% EtOAc in hexanes) gave 162.0 mg (43% yield) of compound **13** as a pale yellow, fluffy solid. R_f (10% EtOAc in hexanes) = 0.17. ¹H NMR (500 MHz, CDCl₃): δ 8.21 (s, 1H, Ar-H), 8.02 (d, J = 8.2 Hz, 1H, Ar-H), 7.49 (s, 1H, Ar-H), 7.39 (dd, J = 1.7, 9.3 Hz, 1H, Ar-H), 5.94 (d, J = 4.4 Hz, 1H, H-1'), 4.96 (s, 2H, NH₂), 4.44 (t, J = 4.4 Hz, 1H, H-2'), 4.28 (t, J = 3.9 Hz, 1H, H-3'), 4.13–4.11 (m, 1H, H-4'), 3.98 (dd, J = 2.7, 11.6 Hz, 1H, H-5'), 3.79 (dd, J = 2.2, 11.5 Hz, 1H, H-5'), 0.96, 0.90, and 0.81 (3s, 27H, *t*-Bu), 0.15, 0.14, 0.09, 0.05, -0.02, and -0.12 (6s, 18H, SiCH₃). ¹³C NMR (125 MHz, CDCl₃): δ 159.2, 158.5, 156.0, 142.0, 140.5, 135.1, 129.5, 126.0, 121.4, 113.2, 108.7, 88.0, 85.3, 76.6, 71.7, 62.4, 26.1, 25.8, 25.7, 18.6, 18.1, 17.9, -4.3, -4.6, -4.8, -4.9, -5.3, -5.4. HRMS (ESI/TOF) calcd for C₃₄H₅₈ClN₈O₅Si₃ [M + H]⁺ 777.3521, found 777.3524.

O⁶-(6-Chlorobenzotriazol-1-yl)-3',5'-di-*O*-(*t*-butyldimethylsilyl)-2'-deoxyguanosine (14).

As described in the synthesis of compound **9**, this reaction was carried out by the reaction of 3',5'-di-*O*-(*t*-butyldimethylsilyl)-2'-deoxyguanosine (300 mg, 0.605 mmol) with PyClocK (671 mg, 1.21 mmol) and DBU (181 μ L, 1.21 mmol) in CH₃CN (5 mL), at room temperature over 22 h. Workup as described for compound **9** and purification by flash chromatography (SiO₂, elution with 20% EtOAc in hexanes) gave 211.6 mg (54% yield) of compound **14** as a white, fluffy solid. R_f (20% EtOAc in hexanes) = 0.40. ¹H NMR (500 MHz, CDCl₃): δ 8.11 (s,

1H, Ar-H), 8.01 (d, J = 8.8 Hz, 1H, Ar-H), 7.50 (d, J = 1.0 Hz, 1H, Ar-H), 7.39 (dd, J = 1.7, 9.5 Hz, 1H, Ar-H), 6.34 (t, J = 6.4 Hz, 1H, H-1'), 4.83 (br s, 2H, NH₂), 4.62–4.59 (m, 1H, H-3'), 4.01–3.99 (m, 1H, H-4'), 3.84 (dd, J = 3.9, 11.2 Hz, 1H, H-5'), 3.77 (dd, J = 2.7, 11.5 Hz, 1H, H-5'), 2.57 (app quint, J_{app} ~ 6.3 Hz, 1H, H-2'), 2.40 (ddd, J = 4.3, 6.0, 12.9 Hz, 1H, H-2'), 0.92 and 0.91 (2s, 18H, *t*-Bu), 0.10, 0.095, and 0.09 (3s, 12H, SiCH₃). ¹³C NMR (125 MHz, CDCl₃): δ 159.2, 158.4, 155.8, 142.0, 140.4, 135.1, 129.5, 126.1, 121.4, 113.4, 108.7, 87.9, 84.1, 71.7, 62.7, 41.2, 26.0, 25.7, 18.4, 18.0, -4.6, -4.8, -5.4, -5.5. HRMS (ESI/TOF) calcd for C₂₈H₄₄ClN₈O₄Si₂ [M + H]⁺ 647.2707, found 647.2693.

2-Bromo-6-(2,3-dibromopropoxy)-2',3',5'-tri-O-(*t*-butyldimethylsilyl)inosine (17).

Compound **17** (26.8 mg, 7% yield) was obtained as a byproduct in the synthesis of **16**, as a white, fluffy solid. R_f (20% EtOAc in hexanes) = 0.59. ¹H NMR (500 MHz, CDCl₃): δ 8.27 and 8.25 (2s, 2H, Ar-H), 6.00 (d, J = 4.4 Hz, 1H, H-1'), 5.99 (d, J = 4.4 Hz, 1H, H-1'), 5.01 (d, J = 4.4 Hz, 2H, OCH₂), 4.69 (s, 1H, H-2'), 4.57 (d, J = 5.9 Hz, 1H, CH), 4.34 (s, 1H, H-3'), 4.16–4.13 (m, 1H, H-4'), 4.04 (dd, J = 4.6, 11.4 Hz, 1H, H-5'), 3.95–3.3 (m, 2H, CH), 3.81 (dd, J = 3.0, 11.7 Hz, 1H, H-5'), 0.96, 0.95, 0.84, and 0.83 (4s, 27H, *t*-Bu), 0.154, 0.15, 0.145, 0.142, 0.13, 0.12, 0.002, -0.001, -0.15, -0.16 (10s, 18H, SiCH₃). HRMS (ESI/TOF) calcd for C₃₁H₅₇Br₃N₄O₅Si₃Na [M + Na]⁺ 909.1079, found 909.1093.

Note. Two purinyl-H and two H-1' resonances were observed in ¹H NMR spectrum of **17**, plausibly due to presence of the C2 chloro analogue that can be formed when these reactions are conducted in CH₂Cl₂. Correspondingly, two purinyl-H resonances (at δ = 8.24 and 8.22 ppm) and two H-1' resonances (doublets at δ = 5.98 ppm, J = 3.9 Hz, and δ = 5.97

ppm, $J = 4.4$ Hz) were also observed in desired compound **16** for the same reason. Data for pure **16** are provided in the paper and herein.

1-[(5,6-Dichloro-1*H*-benzotriazol-1-yl)oxy]-*N,N,N'*-tetramethylphosphanediamine (36).

R_f (50% EtOAc in hexanes) = 0.38. ^1H NMR (500 MHz, CDCl_3): δ 8.33 (s, 1H, Ar-H), 8.15 (s, 1H, Ar-H), 2.73 and 2.71 (2s, 12H, CH_3). ^{13}C NMR (125 MHz, CDCl_3): δ 144.5, 135.2, 133.9, 129.5, 120.3, 115.0, 36.7, 36.5. ^{31}P NMR (202 MHz, CDCl_3): δ 14.63 (relative to 85% aq. H_3PO_4 as external standard). HRMS (ESI/TOF) calcd for $\text{C}_{10}\text{H}_{14}\text{Cl}_2\text{N}_5\text{OPNa}$ [M + Na] $^+$ 344.0205, found 344.0206.

Reduction of 6-(6-chlorobenzotriazol-1-yl)-9-[2,3,5-tri-O-(*t*-butyldimethylsilyl)- β -D-ribofuranosyl]purine (27b).

In a clean, dry 5 mL round-bottomed flask, equipped with a stirring bar, a solution of 6-(6-chlorobenzotriazol-1-yl) nucleoside **27b** (20.0 mg, 26.8 μmol) in anhydrous MeOH (2.0 mL) was prepared. To this was added 10% w/w Pd/C (20.0 mg, 100% wt. equivalent) and Et_3N (7.5 μL , 53.6 μmol). The flask was evacuated and filled with hydrogen gas, and the process was repeated five times. Finally, the mixture was vigorously stirred under a balloon filled with hydrogen gas, for 5 h at room temperature. The mixture was filtered through Celite and the filtrate was evaporated to dryness. The crude material was purified by preparative TLC (500 μm , 20 x 20 cm SiO_2 plate eluted with 30% EtOAc in hexanes) to give 10.3 mg (54% yield) of benzotriazolyl compound **1** as an off-white, oily material. R_f (30% EtOAc in hexanes) = 0.71. An uncharacterized purple, oily product (6.6 mg) was also isolated in this reaction. R_f (30% EtOAc in hexanes) = 0.48.

Reduction of 6-(5-chlorobenzotriazol-1-yl)-9-[3,5-di-O-(*t*-butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (28a).

As described for the reduction of **27b**, this reduction was carried out by the addition of 10% w/w Pd/C (1.0 mg, 10% wt. equivalent) and Et₃N (3.0 μ L, 19.4 μ mol) to a solution of **28a** (10.0 mg, 16.2 μ mol) in anhydrous MeOH (1.0 mL), over 2 h at room temperature, under a balloon filled with hydrogen gas. The mixture was filtered through Celite and the filtrate was evaporated to dryness. The crude material was purified by preparative TLC (500 μ m, 20 x 20 cm SiO₂ plate eluted with 30% EtOAc in hexanes) to give 6.2 mg (66% yield) of benzotriazolyl compound **5** as an off-white solid. R_f (30% EtOAc in hexanes) = 0.33.

Reduction of 6-(6-chlorobenzotriazol-1-yl)-9-[3,5-di-O-(*t*-butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl]purine (28b).


As described in the reduction of **27b**, this reduction was carried out by the addition of 10% w/w Pd/C (20.0 mg, 100% wt. equivalent) and Et₃N (9.0 μ L, 64.9 μ mol) to a solution of **28b** (20.0 mg, 32.4 μ mol) in anhydrous MeOH (2.0 mL), over 5 h at room temperature, under balloon filled with hydrogen gas. The mixture was filtered through Celite and the filtrate was evaporated to dryness. The crude material was purified by preparative TLC (500 μ m, 20 x 20 cm SiO₂ plate eluted with 30% EtOAc in hexanes) to give 9.6 mg (51% yield) of benzotriazolyl compound **5** as an off-white, fluffy solid. R_f (30% EtOAc in hexanes) = 0.45. An uncharacterized purple, oily product (3.2 mg) was also isolated in this reaction. R_f (30% EtOAc in hexanes) = 0.20.

1.603_VB_U1_94_A_1H


Automation directory: /export/home/ppradhan/vnmrsys/data/batch9/p31_batch10



Sample id : tmpstudy



Pulse Sequence: s2pul



TBDMSO TBDSO OTBDMS
2








1203_VB_01_95_A_13C
Automation directory: /export/home/ppradhan/vnmrsys/data/batch9/p31_batch10
Sample id : tmppstudy
Pulse Sequence: s2pul

TBDMSO 5



C[C@H]1CC(OCC[C@H]2N=C3C=CN=C3N2)C[C@H](C1)C[Si](C)(C)C






1203_VB_01_45_1F


```
Automation directory: /export/home/ppradhan/vnmrsys/data/batch9/p31_batch10  
Sample : 1203 VB 01 45 LH  
Sample : 1203 VB 01 45 LH
```



Pulse Sequence: s2pul







































1203_VB_02_84_A_1H
 Automation directory: /export/home/ppradhan/vnmrjsys/data/batch9/p31_batch10
 Sample id : tmsstudy
 Pulse Sequence: s2pul
 TBDMsO OTBDMs
16












1203_VB_01_81_A_1H
 Automation directory: /export/home/ppradhan/vnmrsys/data/batch9/p31_batch10
 Sample id : tmpstudy
 Pulse Sequence: s2pul
 TBDM¹SO OTBDM¹S
18
















1203_VB_01_41_A_1H
 Automation directory: /export/home/ppradhan/vnmrsys/data/batch9/p31_batch10
 Sample id : tmpstudy
 Sample : 1203_VB_01_41_A_1H
 Pulse Sequence: s2pul





1203_VB_01_41_A_13C


Automation directory: /export/home/ppradhan/vnmrsys/data/batch9/p31_batch10

Sample id : tmpstudy

Sample : 1203_VB_01_41_A_13C


Pulse Sequence: s2pul





24
(A = N, B = CH
or A = CH₂, B = N)

TBDMSO





1203_VB_01_52_A_1H


Automation directory: /export/home/ppradhan/vnmrsys/data/batch9/p31_batch10


Sample id : tppstudy

Sample : 1203_VB_01_52_A_1H

Pulse Sequence: s2pul










1203_VB_01_60_A_1H
 Automation directory: /export/home/ppradhan/vnmrsys/data/batch9/p31_batch10
 Sample id : tempstudy
 Sample : 1203_VB_01_60_A_1H
 Pulse Sequence: s2pul

Clc1ccc2c(c1)nc3c(NC=NC3=O)C[C@H]4OC[C@H]4C[C@H](OTBDMS)COTBDMS
27a









Pulse Sequence: s2pul

TBDM_{SO} OTBDM_S


27b


	ppm
1	-0.0
2	1.0
3	2.0
4	3.0
5	4.0
6	5.0
7	6.0
8	7.0
9	8.0
	7.66
	1.09
	0.75
	0.83
	0.71
	0.83
	0.84
	1.00
	1.08
	1.13
	1.22
	1.18
	1.22
	2.51
	9.44
	15.08
	2.65
	7.66



1203_VB_01_58_A_1H
 Automation directory: /export/home/ppradhan/vnmrsys/data/batch9/p31_batch10
 Sample id : tmpstudy
 Sample : 1203_VB_01_58_A_1H
 Pulse Sequence: s2pul

Clc1ccc2c(c1)nc3c(NC=NC3=O)COCC[Si](C)(C)C
28a







1203_VB_01_58_A_NOESY_3



Autonation directory: /export/home/ppradhan/vnmrsys/data/batch9/p31_batch10
Sample id : tmpstudy



Pulse Sequence: NOESY


Solvent: cdc13
Temp: 25.0 C / 298.1 K
Operator: mkl1d
Pulse: 1.03_VB_01_58_A_NOESY_3
INOVA-500 "r7ga"

Relax. delay 1.000 sec
Aqc. time 0.150 sec
Width 600.2 Hz
2D width 600.2 Hz
64 repetitions
2 x 256 increments
OBSERVE H1, 499.7707234 MHz
DATA PROCESSING
Resol1. enhancement 3.4 Hz
Gauss apodization 0.037 sec
F1 DATA PROCESSING
Resol1. enhancement 0.0 Hz
Gauss apodization 0.021 sec
FT size 2048 x 2048
Total time 10 hr, 49 min, 53 sec










TBDMSO OTBDMS
29a

1203_VB_01_89_A_1H_III

Automation directory: /export/home/ppradhan/vnmrstudy/vnmrstudy

Sample id : tmpstudy

Pulse Sequence: s2pul







1203.vb_11_89_A_NOESY_III



Automation directory: /export/home/pbpradhan/vnmrsys/data/batch9/p31_batch10
Sample id : tmpstudy

Pulse Sequence: NOESY

Solvent: cc13
Temp: 25.0 C / 298.1 K
Operator: mk1pd
File: 1203.vb_01_89_A_NOESY_III
INOVA-500 ^1H , ^13C

Relax: delay 1.000 sec
Acq. time 0.150 sec
width 5397.5 Hz
2D width 5397.5 Hz
64 repetitions
2 x 256 increments
OBSERVE H1 499.770221 MHz
DATA PROCESSING
Gauss apodization 0.069 sec
F1 DATA PROCESSING 0.031 sec
FT size 2048 x 2048
Total time 10 hr, 49 min, 55 sec








1203_VB_01_89_B_13C

Automation directory: /export/home/prradhan/vnmrsvs/data/batch9/p31 batch10

Sample id : tmpstudy



Pulse Sequence: s2pul








1203_VB_01_92_MIX_II_13C

Pulse Sequence: s2pw1










1203_VB_02_07_1H_DMSO


Automation directory: /export/home/ppradhan/vnmrjsys/data/batch9/p31_batch10

Sample id : tmpstudy

Pulse Sequence: s2pul

33






33


1203_VB_02_07_13C_DMSO

Automation directory: /export/home/ppradhan/vnmrsys/data/batch9/b31_batch10

Sample id : tmpstudy

Pulse Sequence: s2pul







1203_VB_02_06_1H_DMSO

Automation directory: /export/home/ppradhan/vnmrjsys/data/batch9/p31_batch10

Sample id : tmptstudy

Pulse Sequence: s2pul







1203_VB_02_06_13C_DMSO

Automation directory: /export/home/ppradhan/vnmrjsys/data/batch9/p31_batch10

Sample id : tmptstudy

Pulse Sequence: s2pul







1203_VB_02_11_1H_DMSO

Automation directory: /export/home/ppradhan/vnmrjsys/data/batch9/p31_batch10

Sample id : tmpstudy

Pulse Sequence: s2pul







1203_VB_02_16_1H

Automation directory: /export/home/ppradhan/vnmrsys/data/batch9/p31_batch10

Sample id : tmpstudy

Pulse Sequence: s2pul







1203_VB_02_16_13C

Automation directory: /export/home/ppradhan/vnmrsys/data/batch9/b31_batch10
Sample id : tmpstudy

Pulse Sequence: s2pul








1203_VB_02_16_31P


Automation directory: /export/home/ppradhan/vnmrjsys/data/batch9/p31_batch10



Sample id : tmptstudy



Pulse Sequence: s2pul


















1203_VB_Q2_37_13C
Automation directory: /export/home/ppradhan/vnmrsys/data/batch9/p31_batch10
Sample id : tmppstudy
Pulse Sequence: s2pul

